Jbs N.V. (JBS)
Valuation Overview•Is Jbs N.V. Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Fragile underlying quality score of 40/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is highly bullish, projecting significant upside. This outlook is strongly supported by highly attractive capital returns, driven by a balanced mix of reliable dividends and share buybacks.
JBS struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company demonstrates solid revenue growth (7.1% 3Y CAGR) paired with robust earnings compounding (13.7% EPS 3Y CAGR). However, profitability remains a major concern with severely compressed operating margins (3.8%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $23.9B | +13.0% | +7.1% | +11.8% | +11.2% | |
| EBITDA | $609.1M | — | -0.1% | — | — | |
| Net Income | -$102.1M | +15.4% | -11.2% | — | +9.1% | |
| EPS (Diluted) | $-0.09 | +1201.3% | +13.7% | +43.2% | +20.6% | |
| Free Cash Flow | $239.6M | -73.3% | +25.1% | -25.3% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 11.9% | 12.9% | 14.7% | 14.7% |
| Operating Margin | 3.8% | 4.0% | 5.5% | 5.4% |
| Net Margin | 1.7% | 1.5% | 2.9% | 2.0% |
| FCF Margin | 0.6% | 1.9% | 1.9% | 2.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $0.31 | $0.20 | -35.0% | ||
| Q2'26 | $0.20 | $0.20 | -2.2% | ||
| Q1'26 | $2.26 | $0.39 | -82.7% | ||
| Q4'25 | $0.51 | $0.52 | +2.6% | ||
| Q3'25 | $0.51 | $0.53 | +4.5% | ||
| Q2'25 | $0.47 | $0.23 | -52.4% | ||
| Q2'25 | $0.23 | $0.50 | +111.8% | ||
| Q1'25 | $0.28 | $0.19 | -33.2% |
Total return is -13.8% (1Y), lagging the benchmark by -28.8%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -10.6% | -23.3% | — |
| 1Y | -13.8% | -28.8% | +6.8% |
| 3YCAGR | +4.5% | -19.0% | +29.9% |
| 5YCAGR | +5.4% | -7.9% | +46.2% |
| 10YCAGR | +3.3% | -10.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Jbs N.V. (JBS) valuation, health, and returns.
Jbs N.V. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +216.2% upside to DCF intrinsic value of $36.58)
Jbs N.V. has multiple valuation anchors: DCF Intrinsic Value: $36.58 | Peer Relative Fair Value: $86.97 | Wall Street Analyst Target: $18.17 (implying +55.7% upside). A convergence of these signals offers higher conviction.
Jbs N.V. displays fair financial health with a composite quality score of 40/100, supported by a Altman Z-Score of 1.5 (distress zone), Piotroski F-Score of 8/9, Return on Invested Capital (ROIC) of 3.1%.
Jbs N.V. pays a 13.6% dividend yield, covered by a 79% payout ratio with 6 years of growth, supplemented by a 2.4% buyback yield.
Jbs N.V.'s current growth trajectory is Accelerating. The company achieved +13.0% 1Y revenue growth and +1201.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +7.1%.
Wall Street consensus is Buy based on 4 analysts, beating EPS expectations in 42% of recent quarters with a -3-quarter streak. The consensus price target represents a +55.7% change from current levels.
Investment risks for Jbs N.V. include: -41.0% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.25x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.